SCHEMBL4179742

SCHEMBL4179742

Cc1ccc(-c2cn(C)nc2-c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.51
HSD17B10 Q99714 1/20 0.51
LMNA P02545 4/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
CASP3 P42574 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
SENP7 Q9BQF6 2/20 0.47
SENP6 Q9GZR1 2/20 0.47
POLB P06746 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
STAT3 P40763 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPK13 O15264 1/20 0.47
CSNK1D P48730 1/20 0.47
CSNK1E P49674 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
MAPK14 Q16539 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14235848 0.83 MAPT (0.54) ACHEHSD17B10LMNARAB9ANPC1
SCHEMBL4184447 0.80 PTGS2 (0.65) LMNARAB9ANPC1ALDH1A1GAA
SCHEMBL23212177 0.79 HPRT1 (0.42) ACHEHSD17B10LMNARAB9ANPC1
SCHEMBL27776835 0.79 MEN1 (0.58) LMNARAB9ASMN1; SMN2POLBALDH1A1
SCHEMBL7777709 0.78 PTGS2 (0.53) MAPK13CSNK1DCSNK1EMAPK12MAPK11
SCHEMBL4319645 0.78 MAPT (0.48) ACHEHSD17B10RAB9ASMN1; SMN2POLB
SCHEMBL17385337 0.78 MAPT (0.48) RAB9ASMN1; SMN2POLBALDH1A1L3MBTL1
SCHEMBL7779714 0.77 PTGS2 (0.52) MAPK13CSNK1DCSNK1EMAPK12MAPK11
SCHEMBL18448504 0.77 ACHE (0.64) ACHEHSD17B10LMNARAB9ANPC1
SCHEMBL5094894 0.76 MAP4K4 (0.50) MAPK13CSNK1DCSNK1EMAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071782-B2 Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2011-12-06 US disclosed
US-8071782-B2 Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2011-12-06 US disclosed
US-8071782-B2 Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2011-12-06 US disclosed
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2009-04-09 US disclosed
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2009-04-09 US disclosed
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles JANSSEN PHARMACEUTICA NV (BE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093637-A1 Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles CYP3A4, CYP4B1, CYP2E1 ACHE 1851/4885HSD17B10 1611/4885LMNA 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.